New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
07:44 EDTAZN, NKTR, SLXP, PGNXFDA Anesthetic & Analgesic Drug Products Advisory Committee holds a meeting
The Committee reviews opioid antagonists being developed for opioid induced constipation including Progenics' and Salix Pharmaceuticals' Subcutaneous RELISTOR and Nektar Therapeutics and AstraZeneca's Naloxegol in a meeting being held at FDA Silver Spring, Maryland offices on June 12 at 8 am. Webcast Link
News For AZN;NKTR;SLXP;PGNX From The Last 14 Days
Check below for free stories on AZN;NKTR;SLXP;PGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 14, 2014
12:01 EDTAZNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
August 13, 2014
08:31 EDTAZNAstraZeneca says Phase 3 trials of lesinurad for gout met primary endpoints
AstraZeneca announced top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid. In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone. In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <5.0mg/dL at month 6 compared to febuxostat alone. Although lesinurad 200mg did not achieve statistical significance at month 6, this dose in combination with febuxostat, was superior to placebo plus febuxostat at all other time points. Results from these Phase III clinical trials will be submitted to a scientific meeting later in 2014. The company is proceeding with preparation of regulatory submissions for lesinurad 200mg combination therapy.
August 12, 2014
05:58 EDTAZNStocks with implied volatility movement; P AZN
Subscribe for More Information
August 11, 2014
14:05 EDTSLXPSalix announces results from TARGET 3 trial
Subscribe for More Information
07:06 EDTPGNX, SLXPSalix, Progenics receive FDA PDUFA date of September 29 for Relistor sNDA
Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the FDA has informed Salix that the supplemental New Drug Application for RELISTOR Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29.
August 8, 2014
11:16 EDTSLXPSalix post-earnings pullback unwarranted, says Sterne Agee
Subscribe for More Information
08:12 EDTPGNXProgenics reports Q2 EPS (17c), consensus (14c)
Subscribe for More Information
August 7, 2014
18:41 EDTSLXPOn The Fly: After Hours Movers
Subscribe for More Information
16:16 EDTSLXPSalix sees FY14 EPS $3.16, consensus $6.53
Sees FY14 revenue approximately $1.6B, consensus $1.63B.
16:15 EDTSLXPSalix sees Q3 EPS $1.53, consensus $1.78
Subscribe for More Information
16:14 EDTSLXPSalix reports Q2 EPS $1.59, consensus $1.72
Subscribe for More Information
15:43 EDTPGNXNotable companies reporting before tomorrow's open
Subscribe for More Information
15:33 EDTSLXP Notable companies reporting after market close
Subscribe for More Information
15:31 EDTSLXPNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.
07:41 EDTPGNXProgenics management to meet with Brean Capital
Subscribe for More Information
07:39 EDTNKTRNektar management to meet with Brean Capital
Subscribe for More Information
06:13 EDTAZNDynavax says AZD1419 Phase 1 study met secondary endpoints
Subscribe for More Information
August 6, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:19 EDTAZNShire, AstraZeneca, Smith & Nephew slump amid inversion fears, FT says
Subscribe for More Information
06:33 EDTSLXPSalix upgraded to Buy from Hold at Cantor
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use